Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced that its Tome Foundational Treatment, the company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, priced at $178 per set, or approximately $45 per treatment.

The product will be sold exclusively through tomeskincare.com. Consumers who join a waitlist will receive early access to preorder. The set includes four once-weekly treatments, each consisting of a cup of Bioneedle powder, a tube of Activator solution, and a brush for at-home application.

The Tome Foundational Treatment features the company's proprietary Bioneedle technology, which uses a wild-harvested freshwater sponge called Spongilla lacustris. The product is applied as a mask after mixing the powder and activator solution immediately before use.

Dermata described the launch as the first product in a planned portfolio of consumer skincare offerings under the Tome brand. The San Diego-based company previously announced a strategic shift away from developing prescription products in favor of direct-to-consumer skincare.

"The upcoming commercial launch of our Tome Foundational Treatment is a defining moment for Dermata, our investors, and consumers," said Gerry Proehl, Chief Executive Officer of Dermata Therapeutics. "This product will establish the commercial foundation for our Tome brand, and we believe will demonstrate the versatility of our Bioneedle platform."